Sansure Biotech

Executive Summary

Sansure Biotech is a leading Chinese in vitro diagnostics (IVD) company specializing in infectious disease testing, oncology screening, and women's health. Founded in 2008 and headquartered in Changsha, the company gained prominence during the COVID-19 pandemic by rapidly developing and distributing PCR and antigen test kits, which significantly boosted its scale and brand recognition. With over 1,000 employees, Sansure offers a comprehensive portfolio of diagnostic reagents and instruments, positioning itself as a key player in China's IVD market. The company is publicly traded but lacks a specified ticker, reflecting its listing on a domestic exchange. Post-pandemic, Sansure faces the challenge of sustaining growth as COVID-19 testing demand declines, but it is leveraging its established distribution network and R&D capabilities to expand into other diagnostic areas, including oncology and women's health. The company's ability to innovate and capture market share in these segments will be critical for its long-term revenue diversification.

Upcoming Catalysts (preview)

• Q3 2026Approval of next-generation molecular diagnostic platform for infectious diseases70% success
• Q2 2026Expansion into Southeast Asian markets through strategic partnerships60% success
• Q1 2026Launch of new oncology screening panel in China75% success